A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 over 21 days in Ambulatory Adult Patients with Charcot-Marie-Tooth Disease Type 1 and Type 2

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507892-23-00

Acronym

NMD670-02-0003

Enrollment

Registered

2024-07-11

Start date

2024-08-30

Completion date

2025-10-09

Last updated

2025-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Charcot-Marie-Tooth Disease Type 1 and Type 2

Brief summary

Change from baseline to day 21 in the total distance walked during the 6MWT for NMD670 vs placebo.

Interventions

DRUGNMD670

DRUGPlacebo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline to day 21 in the total distance walked during the 6MWT for NMD670 vs placebo.	—

Countries

Belgium, Denmark, France, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026